دورية أكاديمية

Aspirin versus metformin in pregnancies at high risk of preterm pre-eclampsia in China (AVERT): protocol for a multicentre, double-blind, 3-arm randomised controlled trial

التفاصيل البيبلوغرافية
العنوان: Aspirin versus metformin in pregnancies at high risk of preterm pre-eclampsia in China (AVERT): protocol for a multicentre, double-blind, 3-arm randomised controlled trial
المؤلفون: Liu, Jiao, Shen, Lixia, Nguyen-Hoang, Long, Zhou, Qiongjie, Wang, Chi Chiu, Lu, Xiaohong, Sahota, Daljit, Chong, Ka Chun, Ying, Hao, Gu, Weirong, Zhou, Rong, Yang, Huixia, Jiang, Yanmin, Chen, Dunjin, Li, Xiaotian, Poon, Liona
المساهمون: National Key Research and Development Program of China
المصدر: BMJ Open ; volume 14, issue 4, page e074493 ; ISSN 2044-6055 2044-6055
بيانات النشر: BMJ
سنة النشر: 2024
الوصف: Introduction Pre-eclampsia (PE) affects about 5% of Chinese pregnant women and is a major cause of maternal and perinatal morbidity and mortality. The first trimester screening model developed by the Fetal Medicine Foundation, which uses the Bayes theorem to combine maternal characteristics and medical history together with measurements of biomarkers, has been proven to be effective and has superior screening performance to that of the traditional risk factor-based approach for the prediction of PE. Prophylactic use of low-dose aspirin in women at risk for PE has resulted in a lower incidence of preterm-PE. However, there is no consensus on the preferred aspirin dosage for the prevention of preterm-PE. Evidence has also suggested that metformin has the potential benefit in preventing PE in pregnant women who are at high risk of the disorder. Method and analysis We present a protocol (V.2.0, date 17 March 2022) for the AVERT trial, which is a multicentre, double-blinded, 3-arm randomised controlled trial (RCT) that uses an effective PE screening programme to explore the optimal dosage of aspirin and the role of metformin for the prevention of PE among high-risk pregnant women in China. We intend to recruit 66 000 singleton pregnancies without treatment of low-dose aspirin and metformin at 11–13 weeks’ gestation and all eligible women attending for their first trimester routine scan will be invited to undergo screening for preterm-PE by the combination of maternal factors, mean arterial pressure and placental growth factor. Women found to be at high risk of developing preterm-PE will be invited to take part in the RCT. This study will compare the incidence of preterm-PE with delivery at <37 weeks’ gestation, as the primary outcome, of three different interventional groups: (1) aspirin 75 mg daily, (2) aspirin 150 mg daily and (3) aspirin 75 mg with metformin 1.5 g daily. 957 participants per treatment group are required to detect a significant difference of 59% in the reduction of the incidence of preterm-PE ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1136/bmjopen-2023-074493
الإتاحة: https://doi.org/10.1136/bmjopen-2023-074493Test
حقوق: http://creativecommons.org/licenses/by-nc/4.0Test/
رقم الانضمام: edsbas.11B52445
قاعدة البيانات: BASE